Trevi Therapeutics grew its share prices by 9.85 percent on Friday to finish at $19.07 apiece, after management underscored strong clinical trial results from its treatment candidate for chronic cough.
Speaking at a three-day conference in Europe, Trevi Therapeutics Inc (NASDAQ:TRVI) CEO Jennifer Good and Chief Development Officer James Cassella highlighted that the oral treatment candidate, Haduvio, successfully demonstrated a significant reduction in cough frequency during clinical trials for refractory chronic cough or RCC, and idiopathic pulmonary fibrosis or IPF.
Haduvio is an extended-release formulation of nalbuphine.
Photo by Polina Tankilevitch on Pexels
$15B Market Opportunity
If and when approved, Haduvio could be a company-defining milestone for Trevi Therapeutics Inc (NASDAQ:TRVI).
Based on the latest data from Hyfe, the total addressable market for chronic cough is expected to reach $14 billion to $15 billion by 2035, from only $9 billion in 2024. This marks a 6 percent compounded annual growth rate across the US, the UK, the European Union, and Japan.
As many as 100 million patients globally currently do not have any access to Food and Drug Administration-approved treatment options and rely entirely on off-label neuromodulators with 31 to 40 percent adverse event rates.
While Trevi Therapeutics Inc (NASDAQ:TRVI) has yet to generate commercial revenue from Haduvio, the size of the addressable market suggests meaningful long-term upside should the therapy ultimately secure regulatory approval.
More Clinical Trials
Building on the successful trials, Trevi Therapeutics Inc (NASDAQ:TRVI) is planning to initiate an adaptive design Phase 2b clinical trial for the treatment of patients with non-IPF ILD-related chronic cough in the second half of 2026.
If the trial is initiated as anticipated, the company would expect topline results from the Phase 2b trial in the second half of 2027.
More Hedge Funds Buy In
Even before the release of positive clinical trial data, Haduvio has already been attracting higher institutional interest, indicating that more hedge funds are establishing exposure ahead of upcoming clinical milestones.
According to Insider Monkey’s database, 40 hedge funds held positions in Trevi Therapeutics Inc (NASDAQ:TRVI) at the end of the first quarter of the year, up from 35 funds in the previous quarter.
However, their combined holdings notably dipped by 2 percent, ending only at $479.9 million versus $492.09 million quarter-on-quarter, signaling that investor conviction weakened slightly in the first quarter.
Investors are expected to continue closely monitoring progress for Haduvio, with each clinical and regulatory milestone carrying the potential to significantly reshape Trevi Therapeutics’ long-term growth prospects.
While we acknowledge the risk and potential of TRVI as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than TRVI and that has 10,000% upside potential, check out our report about the cheapest AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.
